ArriVent Posts $40.3M Q3 Loss, $393M Cash Through Mid-2028 as FURVENT Review Continues
AVBP sits 25% above its 52-week low of $11.36.
Summary
ArriVent reported a $40.3M net loss for Q3 2026, with $393.2M in cash and investments that management says funds operations to mid-2028. The quarter's central issue remains firmonertinib: the Phase 3 FURVENT trial missed its primary PFS endpoint, and the company disclosed fuller data — median PFS of 11.0 months versus 9.5 months on chemotherapy (HR 0.75; p=0.0654) and a confirmed ORR of 60% versus 33%. Management is reviewing the dataset, including BICR versus investigator-assessed PFS differences in the chemo arm, and will give a firmonertinib update in Q1 2027. The ADC pipeline is the offset: ARR-217 showed a 44.8% ORR in colorectal cancer at 6 mg/kg, with Phase 1b data expected in the first half of 2027, and ARR-002 has dosed its first patient. Cash burn is steady — $122.2M used in operations over nine months versus $129.9M a year earlier — but the loss of R&D architect and co-founder Stuart Lutzker, alongside a new CMO, leaves execution on the remaining pipeline as the thing to prove.
At the time of this announcement, AVBP was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $698.2M. The 52-week trading range was $11.36 to $35.83. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.